Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Schizophrenia

  Free Subscription


Articles published in Psychol Med

Retrieve available abstracts of 106 articles:
HTML format
Text format



Single Articles


    June 2017
  1. CUI Y, Liu B, Song M, Lipnicki DM, et al
    Auditory verbal hallucinations are related to cortical thinning in the left middle temporal gyrus of patients with schizophrenia.
    Psychol Med. 2017 Jun 19:1-8. doi: 10.1017/S0033291717001520.
    PubMed     Text format     Abstract available


  2. BORA E, Ozerdem A
    Meta-analysis of longitudinal studies of cognition in bipolar disorder: comparison with healthy controls and schizophrenia.
    Psychol Med. 2017 Jun 6:1-14. doi: 10.1017/S0033291717001490.
    PubMed     Text format     Abstract available


    May 2017
  3. WALTON E, Hibar DP, van Erp TGM, Potkin SG, et al
    Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA consortium.
    Psychol Med. 2017 May 26:1-13. doi: 10.1017/S0033291717001283.
    PubMed     Text format     Abstract available


  4. ZHENG W, Li XH, Yang XH, Cai DB, et al
    Adjunctive memantine for schizophrenia: a meta-analysis of randomized, double-blind, placebo-controlled trials.
    Psychol Med. 2017 May 22:1-10. doi: 10.1017/S0033291717001271.
    PubMed     Text format     Abstract available


  5. DI BIASE MA, Cropley VL, Baune BT, Olver J, et al
    White matter connectivity disruptions in early and chronic schizophrenia.
    Psychol Med. 2017 May 22:1-14. doi: 10.1017/S0033291717001313.
    PubMed     Text format     Abstract available


  6. MORITZ S, Klein JP, Desler T, Lill H, et al
    Neurocognitive deficits in schizophrenia. Are we making mountains out of molehills?
    Psychol Med. 2017 May 9:1-11. doi: 10.1017/S0033291717000939.
    PubMed     Text format     Abstract available


  7. BORA E, Binnur Akdede B, Alptekin K
    Neurocognitive impairment in deficit and non-deficit schizophrenia: a meta-analysis.
    Psychol Med. 2017 May 4:1-14. doi: 10.1017/S0033291717000952.
    PubMed     Text format     Abstract available


  8. KRAKAUER K, Ebdrup BH, Glenthoj BY, Raghava JM, et al
    Patterns of white matter microstructure in individuals at ultra-high-risk for psychosis: associations to level of functioning and clinical symptoms.
    Psychol Med. 2017 May 3:1-19. doi: 10.1017/S0033291717001210.
    PubMed     Text format     Abstract available


  9. ALDERSON HL, Semple DM, Blayney C, Queirazza F, et al
    Risk of transition to schizophrenia following first admission with substance-induced psychotic disorder: a population-based longitudinal cohort study.
    Psychol Med. 2017 May 3:1-8. doi: 10.1017/S0033291717001118.
    PubMed     Text format     Abstract available


  10. LEES J, Michalopoulou PG, Lewis SW, Preston S, et al
    Modafinil and cognitive enhancement in schizophrenia and healthy volunteers: the effects of test battery in a randomised controlled trial.
    Psychol Med. 2017 May 3:1-11. doi: 10.1017/S0033291717000885.
    PubMed     Text format     Abstract available


    April 2017
  11. ORANJE B, Aggernaes B, Rasmussen H, Ebdrup BH, et al
    Selective attention and mismatch negativity in antipsychotic-naive, first-episode schizophrenia patients before and after 6 months of antipsychotic monotherapy.
    Psychol Med. 2017 Apr 26:1-11. doi: 10.1017/S0033291717000599.
    PubMed     Text format     Abstract available


  12. PAN YJ, Yeh LL, Chan HY, Chang CK, et al
    Transformation of excess mortality in people with schizophrenia and bipolar disorder in Taiwan.
    Psychol Med. 2017 Apr 26:1-11. doi: 10.1017/S0033291717001040.
    PubMed     Text format     Abstract available


  13. SPENCER BWJ, Shields G, Gergel T, Hotopf M, et al
    Diversity or disarray? A systematic review of decision-making capacity for treatment and research in schizophrenia and other non-affective psychoses.
    Psychol Med. 2017 Apr 26:1-17. doi: 10.1017/S0033291717000502.
    PubMed     Text format     Abstract available


  14. PARELLADA M, Pina-Camacho L, Moreno C, Aleman Y, et al
    Insular pathology in young people with high-functioning autism and first-episode psychosis.
    Psychol Med. 2017 Apr 24:1-11. doi: 10.1017/S0033291717000988.
    PubMed     Text format     Abstract available


  15. OUELLET-PLAMONDON C, Abdel-Baki A, Salvat E, Potvin S, et al
    Specific impact of stimulant, alcohol and cannabis use disorders on first-episode psychosis: 2-year functional and symptomatic outcomes.
    Psychol Med. 2017 Apr 20:1-11. doi: 10.1017/S0033291717000976.
    PubMed     Text format     Abstract available


  16. VERMEULEN J, van Rooijen G, Doedens P, Numminen E, et al
    Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis.
    Psychol Med. 2017 Apr 11:1-12. doi: 10.1017/S0033291717000873.
    PubMed     Text format     Abstract available


  17. DEMJAHA A, Lappin JM, Stahl D, Patel MX, et al
    Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors.
    Psychol Med. 2017 Apr 11:1-9. doi: 10.1017/S0033291717000435.
    PubMed     Text format     Abstract available


  18. KNAPP F, Viechtbauer W, Leonhart R, Nitschke K, et al
    Planning performance in schizophrenia patients: a meta-analysis of the influence of task difficulty and clinical and sociodemographic variables.
    Psychol Med. 2017 Apr 7:1-15. doi: 10.1017/S0033291717000459.
    PubMed     Text format     Abstract available


  19. CHIEN WT, Bressington D, Yip A, Karatzias T, et al
    An international multi-site, randomized controlled trial of a mindfulness-based psychoeducation group programme for people with schizophrenia.
    Psychol Med. 2017 Apr 4:1-16. doi: 10.1017/S0033291717000526.
    PubMed     Text format     Abstract available


    March 2017
  20. EMSLEY R, Asmal L, du Plessis S, Chiliza B, et al
    Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment.
    Psychol Med. 2017 Mar 28:1-10. doi: 10.1017/S0033291717000642.
    PubMed     Text format     Abstract available


  21. BRUCATO G, Masucci MD, Arndt LY, Ben-David S, et al
    Baseline demographics, clinical features and predictors of conversion among 200 individuals in a longitudinal prospective psychosis-risk cohort.
    Psychol Med. 2017 Mar 2:1-13. doi: 10.1017/S0033291717000319.
    PubMed     Text format     Abstract available


    February 2017
  22. VAN RHEENEN TE, Lewandowski KE, Tan EJ, Ospina LH, et al
    Characterizing cognitive heterogeneity on the schizophrenia-bipolar disorder spectrum.
    Psychol Med. 2017 Feb 28:1-17. doi: 10.1017/S0033291717000307.
    PubMed     Text format     Abstract available


  23. FIRTH J, Stubbs B, Sarris J, Rosenbaum S, et al
    The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis.
    Psychol Med. 2017 Feb 16:1-13. doi: 10.1017/S0033291717000022.
    PubMed     Text format     Abstract available


  24. GRONHOLM PC, Thornicroft G, Laurens KR, Evans-Lacko S, et al
    Mental health-related stigma and pathways to care for people at risk of psychotic disorders or experiencing first-episode psychosis: a systematic review.
    Psychol Med. 2017 Feb 15:1-13. doi: 10.1017/S0033291717000344.
    PubMed     Text format     Abstract available


  25. RHINDRESS K, Robinson DG, Gallego JA, Wellington R, et al
    Hippocampal subregion volume changes associated with antipsychotic treatment in first-episode psychosis.
    Psychol Med. 2017 Feb 14:1-13. doi: 10.1017/S0033291717000137.
    PubMed     Text format     Abstract available


  26. XU Y, Qin W, Zhuo C, Xu L, et al
    Selective functional disconnection of the orbitofrontal subregions in schizophrenia.
    Psychol Med. 2017 Feb 10:1-10. doi: 10.1017/S0033291717000101.
    PubMed     Text format     Abstract available


  27. NIELSEN SM, Toftdahl NG, Nordentoft M, Hjorthoj C, et al
    Association between alcohol, cannabis, and other illicit substance abuse and risk of developing schizophrenia: a nationwide population based register study.
    Psychol Med. 2017 Feb 7:1-10. doi: 10.1017/S0033291717000162.
    PubMed     Text format     Abstract available


  28. OCHOA S, Lopez-Carrilero R, Barrigon ML, Pousa E, et al
    Randomized control trial to assess the efficacy of metacognitive training compared with a psycho-educational group in people with a recent-onset psychosis.
    Psychol Med. 2017 Feb 7:1-12. doi: 10.1017/S0033291716003421.
    PubMed     Text format     Abstract available


    January 2017
  29. STONE J, Koychev I, Reilly T, McGuire P, et al
    Reply to: Letter to the Editor: Sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained?
    Psychol Med. 2017 Jan 23:1. doi: 10.1017/S0033291716003470.
    PubMed     Text format    


  30. WOOLLEY JD, Chuang B, Fussell C, Scherer S, et al
    Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls.
    Psychol Med. 2017 Jan 16:1-12. doi: 10.1017/S0033291716003433.
    PubMed     Text format     Abstract available


  31. STUDERUS E, Ramyead A, Riecher-Rossler A
    Prediction of transition to psychosis in patients with a clinical high risk for psychosis: a systematic review of methodology and reporting.
    Psychol Med. 2017 Jan 16:1-16. doi: 10.1017/S0033291716003494.
    PubMed     Text format     Abstract available


  32. IWABUCHI SJ, Palaniyappan L
    Abnormalities in the effective connectivity of visuothalamic circuitry in schizophrenia.
    Psychol Med. 2017 Jan 12:1-11. doi: 10.1017/S0033291716003469.
    PubMed     Text format     Abstract available


    December 2016
  33. BORA E, Akdede BB, Alptekin K
    The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis.
    Psychol Med. 2016 Dec 29:1-11. doi: 10.1017/S0033291716003366.
    PubMed     Text format     Abstract available


  34. LIU M, Malone SM, Vaidyanathan U, Keller MC, et al
    Psychophysiological endophenotypes to characterize mechanisms of known schizophrenia genetic loci.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  35. MAIA-DE-OLIVEIRA JP, Baker GB, Dursun SM, Hallak JE, et al
    Letter to the Editor: Sodium nitroprusside for schizophrenia: could methodological variables account for the different results obtained?
    Psychol Med. 2016.
    PubMed     Text format    


  36. GAGE SH, Jones HJ, Burgess S, Bowden J, et al
    Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  37. STILO SA, Gayer-Anderson C, Beards S, Hubbard K, et al
    Further evidence of a cumulative effect of social disadvantage on risk of psychosis.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


    November 2016
  38. WU C, Zheng Y, Li J, Wu H, et al
    Brain substrates underlying auditory speech priming in healthy listeners and listeners with schizophrenia.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  39. RAPADO-CASTRO M, Dodd S, Bush AI, Malhi GS, et al
    Cognitive effects of adjunctive N-acetyl cysteine in psychosis.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  40. CHANG WC, Kwong VW, Hui CL, Chan SK, et al
    Relationship of amotivation to neurocognition, self-efficacy and functioning in first-episode psychosis: a structural equation modeling approach.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  41. KLAAS HS, Clemence A, Marion-Veyron R, Antonietti JP, et al
    Insight as a social identity process in the evolution of psychosocial functioning in the early phase of psychosis.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  42. LANGE EH, Nerland S, Jorgensen KN, Morch-Johnsen L, et al
    Alcohol use is associated with thinner cerebral cortex and larger ventricles in schizophrenia, bipolar disorder and healthy controls.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  43. MCHUGH MJ, McGorry PD, Yung AR, Lin A, et al
    Cannabis-induced attenuated psychotic symptoms: implications for prognosis in young people at ultra-high risk for psychosis.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


    October 2016
  44. RYDKJAER J, Mollegaard Jepsen JR, Pagsberg AK, Fagerlund B, et al
    Mismatch negativity and P3a amplitude in young adolescents with first-episode psychosis: a comparison with ADHD.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  45. SHAH C, Zhang W, Xiao Y, Yao L, et al
    Common pattern of gray-matter abnormalities in drug-naive and medicated first-episode schizophrenia: a multimodal meta-analysis.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  46. RIKANDI E, Pamilo S, Mantyla T, Suvisaari J, et al
    Precuneus functioning differentiates first-episode psychosis patients during the fantasy movie Alice in Wonderland.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  47. VEERMAN SR, Schulte PF, Deijen JB, de Haan L, et al
    Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  48. PRUESSNER M, Bechard-Evans L, Pira S, Joober R, et al
    Interplay of hippocampal volume and hypothalamus-pituitary-adrenal axis function as markers of stress vulnerability in men at ultra-high risk for psychosis.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  49. SCHMIDT A, Antoniades M, Allen P, Egerton A, et al
    Longitudinal alterations in motivational salience processing in ultra-high-risk subjects for psychosis.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  50. ROCCA P, Galderisi S, Rossi A, Bertolino A, et al
    Social cognition in people with schizophrenia: a cluster-analytic approach.
    Psychol Med. 2016;46:2717-29.
    PubMed     Text format     Abstract available


    September 2016
  51. STONE JM, Morrison PD, Koychev I, Gao F, et al
    The effect of sodium nitroprusside on psychotic symptoms and spatial working memory in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  52. STEEL C, Hardy A, Smith B, Wykes T, et al
    Cognitive-behaviour therapy for post-traumatic stress in schizophrenia. A randomized controlled trial.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  53. FRAJO-APOR B, Kemmler G, Pardeller S, Plass T, et al
    Emotional intelligence and non-social cognition in schizophrenia and bipolar I disorder.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  54. VELING W, Counotte J, Pot-Kolder R, van Os J, et al
    Childhood trauma, psychosis liability and social stress reactivity: a virtual reality study.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  55. LALLY J, Ajnakina O, Di Forti M, Trotta A, et al
    Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  56. FISZDON JM, Choi KH, Bell MD, Choi J, et al
    Cognitive remediation for individuals with psychosis: efficacy and mechanisms of treatment effects.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  57. CHEN DC, Du XD, Yin GZ, Yang KB, et al
    Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


    August 2016
  58. O'REILLY K, O'Connell P, Donohoe G, Coyle C, et al
    Anticholinergic burden in schizophrenia and ability to benefit from psychosocial treatment programmes: a 3-year prospective cohort study.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  59. RINGEN PA, Nesvag R, Helle S, Lagerberg TV, et al
    Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  60. HODGINS S, Larm P, Westerman J
    Individuals developing schizophrenia are hidden among adolescent substance misusers.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


    July 2016
  61. PERALTA V, Cuesta MJ
    Delusional disorder and schizophrenia: a comparative study across multiple domains.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  62. RENTZSCH J, Koller K, Kronenberg G
    Letter to the Editor: Disentangling cause and effect in the relationship between cannabis and psychosis: are we there yet?
    Psychol Med. 2016.
    PubMed     Text format    


  63. MIKOLAS P, Melicher T, Skoch A, Matejka M, et al
    Connectivity of the anterior insula differentiates participants with first-episode schizophrenia spectrum disorders from controls: a machine-learning study.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  64. RIMVALL MK, Clemmensen L, Munkholm A, Rask CU, et al
    Introducing the White Noise task in childhood: associations between speech illusions and psychosis vulnerability.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  65. REININGHAUS U, Gayer-Anderson C, Valmaggia L, Kempton MJ, et al
    Psychological processes underlying the association between childhood trauma and psychosis in daily life: an experience sampling study.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  66. WANG C, Ji F, Hong Z, Poh JS, et al
    Disrupted salience network functional connectivity and white-matter microstructure in persons at risk for psychosis: findings from the LYRIKS study.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


    June 2016
  67. FINEBERG SK, Leavitt J, Deutsch-Link S, Dealy S, et al
    Self-reference in psychosis and depression: a language marker of illness.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  68. HU M, Zong X, Zheng J, Mann JJ, et al
    Risperidone-induced topological alterations of anatomical brain network in first-episode drug-naive schizophrenia patients: a longitudinal diffusion tensor imaging study.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  69. HUI CL, Li YK, Li AW, Lee EH, et al
    Visual working memory deterioration preceding relapse in psychosis.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  70. DE BONT PA, van den Berg DP, van der Vleugel BM, de Roos C, et al
    Prolonged exposure and EMDR for PTSD v. a PTSD waiting-list condition: effects on symptoms of psychosis, depression and social functioning in patients with chronic psychotic disorders.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  71. BERGINK V, Laursen TM, Johannsen BM, Kushner SA, et al
    Letter to the Editor: Postpartum psychosis and pre-eclamptic toxaemia: a reply.
    Psychol Med. 2016.
    PubMed     Text format    


  72. CHEN LJ, Steptoe A, Chung MS, Ku PW, et al
    Association between actigraphy-derived physical activity and cognitive performance in patients with schizophrenia.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  73. BROCKINGTON I
    Letter to the Editor Postpartum psychosis and pre-eclamptic toxaemia.
    Psychol Med. 2016.
    PubMed     Text format    


  74. JUNG E, Wiesjahn M, Wendt H, Bock T, et al
    Symptoms, functioning and coping strategies in individuals with schizophrenia spectrum disorders who do not take antipsychotic medication: a comparative interview study.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  75. HARING L, Muursepp A, Mottus R, Ilves P, et al
    Cortical thickness and surface area correlates with cognitive dysfunction among first-episode psychosis patients.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


    May 2016
  76. GUO S, Palaniyappan L, Liddle PF, Feng J, et al
    Dynamic cerebral reorganization in the pathophysiology of schizophrenia: a MRI-derived cortical thickness study.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  77. BAKKER G, Caan MW, Schluter RS, Bloemen OJ, et al
    Distinct white-matter aberrations in 22q11.2 deletion syndrome and patients at ultra-high risk for psychosis.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  78. LEE EH, Hui CL, Chang WC, Chan SK, et al
    Letter to the Editor: Comparison of cognitive functions, pre-morbid conditions and clinical characteristics between brief psychotic disorder and schizophrenia.
    Psychol Med. 2016.
    PubMed     Text format    


  79. O'DONOGHUE B, Lyne JP, Renwick L, Lane A, et al
    Neighbourhood characteristics and the incidence of first-episode psychosis and duration of untreated psychosis.
    Psychol Med. 2016;46:1367-78.
    PubMed     Text format     Abstract available


    April 2016
  80. CABRERA B, Bioque M, Penades R, Gonzalez-Pinto A, et al
    Cognition and psychopathology in first-episode psychosis: are they related to inflammation?
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  81. KIMHY D, Gill KE, Brucato G, Vakhrusheva J, et al
    The impact of emotion awareness and regulation on social functioning in individuals at clinical high risk for psychosis.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  82. JORGENSEN KN, Nerland S, Norbom LB, Doan NT, et al
    Increased MRI-based cortical grey/white-matter contrast in sensory and motor regions in schizophrenia and bipolar disorder.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  83. VEERMAN SR, Schulte PF, Smith JD, de Haan L, et al
    Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  84. CROSSLEY NA, Fox PT, Bullmore ET
    Meta-connectomics: human brain network and connectivity meta-analyses.
    Psychol Med. 2016;46:897-907.
    PubMed     Text format     Abstract available


    March 2016
  85. MORGAN C, John S, Esan O, Hibben M, et al
    The incidence of psychoses in diverse settings, INTREPID (2): a feasibility study in India, Nigeria, and Trinidad.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  86. VAN OMMEN MM, van Beilen M, Cornelissen FW, Smid HG, et al
    The prevalence of visual hallucinations in non-affective psychosis, and the role of perception and attention.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  87. ISING HK, Ruhrmann S, Burger NA, Rietdijk J, et al
    Development of a stage-dependent prognostic model to predict psychosis in ultra-high-risk patients seeking treatment for co-morbid psychiatric disorders.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  88. WANG Q, Cheng W, Li M, Ren H, et al
    The CHRM3 gene is implicated in abnormal thalamo-orbital frontal cortex functional connectivity in first-episode treatment-naive patients with schizophrenia.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  89. RIGUCCI S, Marques TR, Di Forti M, Taylor H, et al
    Effect of high-potency cannabis on corpus callosum microstructure.
    Psychol Med. 2016;46:841-54.
    PubMed     Text format     Abstract available


    February 2016
  90. FORTGANG RG, Hultman CM, van Erp TG, Cannon TD, et al
    Multidimensional assessment of impulsivity in schizophrenia, bipolar disorder, and major depressive disorder: testing for shared endophenotypes.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


  91. FETT AJ, Shergill SS, Korver-Nieberg N, Yakub F, et al
    Learning to trust: trust and attachment in early psychosis.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


    January 2016
  92. PU W, Luo Q, Palaniyappan L, Xue Z, et al
    Failed cooperative, but not competitive, interaction between large-scale brain networks impairs working memory in schizophrenia.
    Psychol Med. 2016.
    PubMed     Text format     Abstract available


    December 2015
  93. BEGEMANN MJ, Daalman K, Heringa SM, Schutte MJ, et al
    Letter to the Editor: Childhood trauma as a risk factor for psychosis: the confounding role of cognitive functioning.
    Psychol Med. 2015.
    PubMed     Text format    


  94. HUI CL, Lee EH, Chang WC, Chan SK, et al
    Letter to the Editor: Comparing delusional disorder and schizophrenia: a comment on Hui et al. (2015) - a reply.
    Psychol Med. 2015.
    PubMed     Text format    


  95. PERALTA V, Cuesta MJ
    Letter to the Editor: Comparing delusional disorder and schizophrenia: a comment on Hui et al. (2015).
    Psychol Med. 2015.
    PubMed     Text format    


  96. GERSTENBERG M, Theodoridou A, Traber-Walker N, Franscini M, et al
    Adolescents and adults at clinical high-risk for psychosis: age-related differences in attenuated positive symptoms syndrome prevalence and entanglement with basic symptoms.
    Psychol Med. 2015.
    PubMed     Text format     Abstract available


  97. FONSECA-PEDRERO E, Debbane M, Schneider M, Badoud D, et al
    Schizotypal traits in adolescents with 22q11.2 deletion syndrome: validity, reliability and risk for psychosis.
    Psychol Med. 2015.
    PubMed     Text format     Abstract available


  98. BIANCONI F, Bonomo M, Marconi A, Kolliakou A, et al
    Differences in cannabis-related experiences between patients with a first episode of psychosis and controls.
    Psychol Med. 2015.
    PubMed     Text format     Abstract available


  99. BARKER V, Bois C, Johnstone EC, Owens DG, et al
    Childhood adversity and cortical thickness and surface area in a population at familial high risk of schizophrenia.
    Psychol Med. 2015.
    PubMed     Text format     Abstract available


  100. VREEKER A, Boks MP, Abramovic L, Verkooijen S, et al
    High educational performance is a distinctive feature of bipolar disorder: a study on cognition in bipolar disorder, schizophrenia patients, relatives and controls.
    Psychol Med. 2015.
    PubMed     Text format     Abstract available


  101. LEVINE SZ, Levav I, Goldberg Y, Pugachova I, et al
    Exposure to genocide and the risk of schizophrenia: a population-based study.
    Psychol Med. 2015.
    PubMed     Text format     Abstract available


    November 2015
  102. KRAAN T, Velthorst E, Koenders L, Zwaart K, et al
    Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis.
    Psychol Med. 2015.
    PubMed     Text format     Abstract available


    July 2015
  103. VELING W, Susser E, Selten JP, Hoek HW, et al
    Social disorganization of neighborhoods and incidence of psychotic disorders: a 7-year first-contact incidence study.
    Psychol Med. 2015;45:1789-98.
    PubMed     Text format     Abstract available


    May 2015
  104. WICKHAM S, Sitko K, Bentall RP
    Insecure attachment is associated with paranoia but not hallucinations in psychotic patients: the mediating role of negative self-esteem.
    Psychol Med. 2015;45:1495-507.
    PubMed     Text format     Abstract available


    April 2015
  105. VELIKONJA T, Fisher HL, Mason O, Johnson S, et al
    Childhood trauma and schizotypy: a systematic literature review.
    Psychol Med. 2015;45:947-63.
    PubMed     Text format     Abstract available


  106. FETT AK, Shergill SS, Krabbendam L
    Social neuroscience in psychiatry: unravelling the neural mechanisms of social dysfunction.
    Psychol Med. 2015;45:1145-65.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: